Alterations of the p53, Rb and p27 tumor suppressor pathways in diffuse large B-cell lymphomas

Anticancer Research

Volumn 27, Issue 4 B, 2007, Pages 2345-2352

  Bai, Maria ^a,b   Tsanou, Elena ^a   Skyrlas, Angelos ^a   Sainis, Ioannis ^a   Agnantis, Niki ^a   Kanavaros, Panagiotis ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cell cycle; Diffuse large B cell lymphomas

Indexed keywords

CYCLIN A; DNA; KI 67 ANTIGEN; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CANCER INHIBITION; CELL PROLIFERATION; CENTROSOME; DNA REPLICATION; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL;

B-LYMPHOCYTES; CELL DIFFERENTIATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34547761368     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Pileri SA, Dirnhofer S, Went P, Ascani S, Sabattini E, Marafioti T, Tzankov A, Leoncini L, Falini B and Zinzani PL: Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology 41: 482-509, 2002.
2. de Leval L and Harris NL : Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology 43: 509-528, 2003.
3. Moller MB, Pedersen NT and Christensen BE: Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation - a population-based study of 1575 cases. Br J Haematol 124: 151-159, 2004.
4. Shaffer AL, Rosenwald A and Staudt LM: Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2: 920-932, 2002.
5. Rossi D and Gaidano G: Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis. Hematology 7: 239-252, 2002.
6. Leoncini L, Lazzi S, Bellan C and Tosi P: Cell kinetics and cell cycle regulation in lymphomas. J Clin Pathol 55: 648-655, 2002.
7. Sanchez-Beato M, Sanchez-Aguilera A and Piris MA: Cell cycle deregulation in B-cell lymphomas. Blood 101: 1220-1235, 2003.
8. Bai M, Skyrlas A, Agnantis NJ, Kamina S, Papoudou-Bai A, Kitsoulis P and Kanavaros P: Relationships between B-cell differentiation, apoptosis and proliferation in diffuse large B-cell lymphomas. Anticancer Res 25: 347-362, 2005.
9. Berglund M, Enblad G, Flordal E, Lui WO, Backlin C, Thunberg U, Sundstrom C, Roos G, Allender SV, Erlanson M, Rosenquist R, Larsson C and Lagercrantz S: Chromosomal imbalances in diffuse large B-cell lymphoma detected by comparative genomic hybridization. Mod Pathol 15: 807-816, 2002.
10. Hans CP, Weisenburger DD, Greiner TC, Chan WC, Aoun P, Cochran GT, Pan Z, Smith LM, Lynch JC, Bociek RG, Bierman PJ, Vose JM and Armitage JO: Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 18: 1377-1384, 2005.
11. Lim MS, Adamson A, Lin Z, Perez-Ordonez B, Jordan RCK, Tripp S, Perkins SL and Elenitoba-Johnson KSJ: Expression of Skp2, a p27 Kip1 ubiqutin ligase, in malignant lymphoma: correlation with p27 Kip1 and proliferation index. Blood 100: 2950-2956, 2002.
12. WAF1/CIP1 and mdm2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, mdm2, p21-immunophenotype associated with missense p53 mutations. J Pathol 181: 51-61, 1997.
13. Villuendas R, Sanchez-Beato M, Martinez JC, Saez A, Martinez-Delgado B, Garcia J, Sol-Mateo M, Sanchez-Verde L, Beniter J, Martinez P and Piris M: Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol 153: 887-897, 1998.
14. Tzardi M, Kouvidou C, Panayiotides J, Stefanaki S, Koutsoubi K, Zois E, Rontogianni D, Eliopoulos G, Delides G and Kanavaros P: p53 protein expression in non-Hodgkin's lymphomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1. J Clin Pathol (Mol Pathol) 49: M278-283, 1996.
15. Sanchez E, Chacon I, Plaza MM, Munoz E, Cruz B, Martinez B, Lopez L, Martinez-Montero JC, Orradre JL, Saez AI, Garcia JF and Piris M: Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 16: 1931-1939, 1998.
16. Stefanaki, K, Tzardi M, Kouvidou C, Rontogianni D, Bolioti S, Chaniotis V, Vlychou M, Delides G and Kanavaros P: Expression of p53, mdm2, p21, Rb, Ki67, bcl2 and bax proteins in lymphomas of the mucosa-associated lymphoid tissue. Anticancer Res 18: 2403-2408, 1998.
17. Lin Z, Lim S and Lim MS: Growth regulation by p27 Kip1 is abrogated by multiple mechanisms in aggressive malignant lymphomas. Br J Haematol 121: 739-748, 2003.
18. Sanchez-Beato M, Camacho FI, Martinez-Montero JC, Saez AI, Villuendas R, Sanchez-Verde L, Garcia JF and Piris MA: Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression and P27/KIP1-cyclin D3 colocalization in tumor cells. Blood 94: 765-772, 1999.
19. Erlanson M, Portin C, Linderholm B, Lindh J, Roos G and Landberg G: Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood 92: 770-777, 1998.
20. Moller MB, Nielsen O and Pedersen NT: Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. Mod Pathol 12: 1010-1016, 1999.
21. Geradts J, Andriko JW and Abbondanzo SL: Loss of tumor suppressor gene expression in high grade but not in low grade non-Hodgkin's lymphomas. Am J Clin Pathol 109: 669-674, 1998.
22. Nakamura M, Sakaki T, Hashimoto H, Nakase H, Oshida E, Shimada K and Konishi N: Frequent alterations of the pl4/ARF and p16/INK4a genes in primary central nervous system lymphomas. Cancer Res 61: 6335-6339, 2001.
23. Moller MB, Ino Y, Gerdes AM, Skjodt K, Louis DN and Pedersen NT: Aberrations of the p53 pathway components p53, mdm2 and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia 13: 453-459, 1999.
24. Moller MB, Kania PW, Ino Y, Gerdes AM, Nielsen O, Louis DN, Skjodt K and Pedersen NT: Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16 INK4A. Leukemia 14: 898-904, 2000.
25. Pabst T, Peters UR, Tinguely M, Scwaller J, Tschan M, Aebi S, Vonlanthev S, Borisch B, Betticher DC, Zimmerman A, Tobler A and Fey MF: Divergent expression of cyclin-dependent kinase inhibitors (Cki) and P14ARF/p16beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemia. Leuk Lymphoma 37: 639-648, 2000.
26. Gronbaek K, de Nully Brown P, Moller MB, Nedergaard T, Ralfkiaer E, Moller P, Zeuthen J and Guldberg P: Concurrent disruption of p16/INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia 14: 1727-1735, 2001.
27. Sanchez-Beato M, Saez AI, Navas IC, Algara P, Sol Mateo M, Villuendas R, Sanchez-Aguilera A, Camacho FI, Sanchez E and Piris MA: Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16 and p27. Am J Pathol 159: 205-213, 2001.
28. Bai M, Vlachonikolis J, Agnantis NJ, Tsanou E, Dimou S, Nicolaides C, Stefanaki S, Pavlidis N and Kanavaros P: Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas. Mod Pathol 14: 1105-1113, 2001.
29. Pinyol M, Hernandez L, Martinez A, Cobo F, Hernandez L, Bea S, Lopez-Guillermo A, Nayach I, Palacin A, Nadal A, Fernandez P, Montserrat E, Cardesa A and Campo E: INKA4/ ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 156: 1987-1996, 2002.
30. Sanchez-Aguilera A, Sanchez-Beato M, Garcia JF, Prieto I, Pollan M and Piris MA: p14 (ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppresor pathways. Blood 99: 1411-1418, 2002.
31. Saez AI, Saez AJ, Artiga MJ, Rosado-Perez A, Camacho FI, Diez A, Garcia JF, Fraga M, Bosch R, Rodriguez-Pinnila SM, Mollejo M, Romero C, Sanchez-Verde L, Pollan M and Piris MA: Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol 164: 613-622, 2004.
32. Paik JH, Jeon YK, Park SS, Kim YA, Kim JE, Huh J, Lee SS, Kim WH and Kim CW: Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal center and non-germinal center B-like diffuse large B-cell lymphomas. Histopathology 47: 281-291, 2005.
33. Huang Q, Ai L, Zhang ZY, Fan CY and Weiss LM: Promoter hypermethylation and protein expression of the p16 gene: analysis of 43 cases of B-cell primary gastric lymphomas from China. Mod Pathol 17: 416-422, 2004.
34. Kuttler F, Valnet-Rabier MB, Angonin R, Ferrand C, Decininck E, Mougin C, Cahn JY and Fest T: Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia 16: 726-735, 2002.
35. Bai M, Tsanou E, Agnantis NJ, Dimou D, Chaidos A, Skyrlas A, Dimou S, Vlychou M, Galani V and Kanavaros P: Expression of cyclin D3 and cyclin E and identification of distinct clusters of proliferative activity and apoptosis status in diffuse large B-cell lymphomas. Histol Histopathol 18: 449-457, 2003.
36. Sherr CJ: The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60: 3689-3695, 2000.
37. Malumbres M and Barbacid M: To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1: 222-231, 2001.
38. Smits V and Medema R: Checking out the G2/M transition. Biochim Biophys Acta 1519: 1-12, 2001.
39. Murray AW: Recycling the cell cycle: cyclins revisited. Cell 116: 221-234, 2004.
40. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JD, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO and Staudt LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000.
41. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fischer RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T and Staudt LM: The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 346: 1937-1947, 2002.
42. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC and Golub TR: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8: 68-74, 2002.
43. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A and Staudt LM: A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 19: 9991-9996, 2003.
44. Lossos IS, Alizadeh AA, Eisen MB, Chan WC, Brown PO, Botstein D, Staudt LM and Levy R: Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large B cell lymphoma. Proc Natl Acad Sci USA 97: 10290-10213, 2000.
45. Davis RE, Brown KD, Siebenlist U and Staudt LM: Constitutive nuclear factor KappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194: 1861-1874, 2001.
46. Feuerhake F, Kutok JL, Monti S, Chen W, La Caske AS, Cattoreti G, Kurtin P, Pinkus GS, deLeval L, Harris NL, Neuberg DS, Habermann TM, Dalla-Favera R, Golub TR, Aster JC and Shipp MA: NF-κB activity, function, and target gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 106: 1392-1399, 2005.
47. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farihna P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO and Chan WC: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275-282, 2003.
48. Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, Colomer D, Falini B, Montserrat E and Campo E: Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 101: 78-84, 2003.
49. Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B, Kajdacsy-Balla A and Perkins SL: Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 28: 464-470, 2004.
50. Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlanson M, Linderoth J, Dictor M, Jerkeman M, Cavallin-Stahl E, Sundstrom C, Rehn-Eriksson S, Backlin C, Hagberg H, Rosenquist R and Enblad G: Evaluation of immunophenotype in diffuse large B-cell lymphomas and its impact on prognosis. Mod Pathol 18: 1113-1120, 2005.
51. King BE, Chen C, Lotker J, Kant J, Okuyama K, Falini B and Swerdlow SH: Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas. Mod Pathol 13: 1219-1231, 2000.
52. Bai M, Agnantis NJ, Skyrlas A, Tsanou E, Kamina S, Galani V and Kanavaros P: Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas. Mod Pathol 16: 471-480, 2003.
53. Bai M, Skyrlas A, Agnantis NJ, Tsanou E, Kamina S, Galani V and Kanavaros P: Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the anti-apoptotic protein bcl-xl. Mod Pathol 17: 847-856, 2004.
54. Bai M, Skyrlas A, Agnantis NJ, Kamina S, Kitsoulis P and Kanavaros P: Cluster analysis of apoptosis-associated bcl2 family proteins in diffuse large B-cell lymphomas. Relations with the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes. Anticancer Res 24: 3081-3088, 2004.
55. Bai M, Tsanou E, Agnantis NJ, Kamina S, Grepi C, Stefanaki K, Rontogianni D, Galani V and Kanavaros P: Proliferation profile of classical Hodgkin's lymphomas. Increased expression of the protein cyclin D2 in Hodgkin and Reed-Sternberg cells. Mod Pathol 17: 1338-1345, 2004.
56. Kanavaros P, Bai M, Stefanaki K, Poussias G, Zioga E, Rontogianni D, Gorgoulis V and Agnantis NJ: Expression of p53, mdm2, p21, Rb, p16, cyclin D1, cyclin A, cyclin B1 and Ki-67 proteins and apoptotic index in T-cell lymphomas. Histol Histopathol 16: 377-386, 2001.
57. Kanavaros P, Stefanaki K, Rontogianni D, Papalazarou D, Arvanitis D, Vamvouka C, Gorgoulis V, Siatitsas I, Agnantis NJ and Bai M: Immunohistochemical expression of p53, p21/waf1, Rb, p16, cyclin D1, p27, Ki67, cyclin A, cyclin B1, bcl2, bax and bak proteins and apoptotic index in normal thymus. Histol Histopathol 16: 1005-1012, 2001.
58. Brooks AR, Shiffman D, Chan CS, Brooks EE and Milner PG: Functional analysis of the human cyclin D2 and cyclin D3 promoters. J Biol Chem 271: 9090-9099, 1996.